Efficacy and safety of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer: A single-center experience

Table 3 Adverse reactions, n (%)

AEs	Grade 1	Grade 2	Grade 3
White blood cell decreased	0 (0)	1 (16.7)	0 (0)
Neutropenia	1 (16.7)	1 (16.7)	0 (0)
Anemia	4 (66.7)	0 (0)	0 (0)
Thrombocytopenia	2 (33.3)	0 (0)	0 (0)
Alanine aminotransferase increased	5 (83.3)	0 (0)	0 (0)
Aspartate aminotransferase increased	5 (83.3)	0 (0)	0 (0)
Urinary protein increased	0 (0)	1 (16.7)	0 (0)
Fatigue	0 (0)	0 (0)	0 (0)
Anorexia	0 (0)	0 (0)	0 (0)
Hypertension	0 (0)	1 (16.7)	0 (0)
Hemorrhage	0 (0)	0 (0)	0 (0)
Palmar-plantar erythrodysesthesia syndrome	0 (0)	0 (0)	1 (16.7)
Hypothyroidism	2 (33.3)	1 (16.7)	0 (0)
Myocarditis	1 (16.7)	0 (0)	0 (0)

AEs: Adverse events.